Table 1 Clinical characteristics of emphysema patients and control individuals with and without AAT-deficiency.
From: Circulating monocytes from healthy individuals and COPD patients
Subject group characteristics | Control subjects M-AAT n= 20 | Healthy subjects Z-AAT n = 10 | COPD patients Z-AAT n = 10 | COPD patients M-AAT n = 10 |
|---|---|---|---|---|
Male/Female | 11/9 | 5/5 | 5/5 | 5/5 |
Age (years) | 53 ± 9.6 | 47.4 ± 11 | 57 ± 12 | 59.4 ± 6.7 |
Smoking history: | ||||
Never smokers | 9 | 6 | 3 | 0 |
Exsmokersa | 10 | 3 | 6 | 8 |
Smokers b | 1 | 1 | 1 | 2 |
FEV1 % of predictedc | 95.9 ± 17 | 94 ± 12 | 43 ± 13 | 37 ± 16 |
FVC % of predicted | 92.8 ± 17 | 94 ± 14 | 63 ± 12 | 50 ± 15 |
FEV1/FVC% ratio | 76 ± 8 | 77 ± 10 | 50 ± 15 | 40 ± 20 |
Medication | ||||
No medication | 20 | 6 | - | - |
Inhaled corticosteroids | - | 3 | 7 | 10 |
Bronchodilatators | - | - | 10 | 8 |
Diuretics | - | - | 3 | 3 |
Continuous oxygen | - | - | 1 | 1 |
Anti-inflammatory | - | - | - | - |
Anti-depressants | - | 1 | - | 1 |